Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival ; volume:38 ; number:7 ; day:27 ; month:5 ; year:2021 ; pages:3831-3841 ; date:7.2021
Advances in therapy ; 38, Heft 7 (27.5.2021), 3831-3841, 7.2021
- Urheber
-
Maj-Hes, Agnieszka
Szarvas, Tibor
Sevcenco, Sabina
Kramer, Gero
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-021-01778-8
- URN
-
urn:nbn:de:101:1-2021101719293589152784
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Maj-Hes, Agnieszka
- Szarvas, Tibor
- Sevcenco, Sabina
- Kramer, Gero
- SpringerLink (Online service)
Ähnliche Objekte (12)
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
β-Arrestin2 promotes docetaxel resistance of castration-resistant prostate cancer via promoting hnRNP A1-mediated PKM2 alternative splicing
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
β-Arrestin2 promotes docetaxel resistance of castration-resistant prostate cancer via promoting hnRNP A1-mediated PKM2 alternative splicing
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
β-Arrestin2 promotes docetaxel resistance of castration-resistant prostate cancer via promoting hnRNP A1-mediated PKM2 alternative splicing
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting